Monocytic transition in B‐lymphoblastic leukaemia with a DUX4 rearrangement
British Journal of Haematology · 2026-05 · 208 (5) · 1519-1520
DOI: 10.1111/bjh.70407 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 06.03.2026. Verfasst von Jingwei Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pathology & Laboratory Medicine, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, USA. Die Arbeit nennt 4 Literaturangaben.
Abstract (Originalsprache)
A 3-year-old female presented with a 1-week history of fevers and lethargy. Peripheral blood studies showed anaemia (haemoglobin: 79 g/L), thrombocytopenia (platelet count: 53× 109/L) and a normal leucocyte count (leucocyte count: 7.42 × 109/L) with 40% circulating blasts. Bone marrow evaluation revealed B-lymphoblastic leukaemia (B-ALL) without significant expression of myelomonocytic antigens by leukaemic blasts (Figure, top row left to right: blast morphology [Wright–Giemsa stain, objective x100 magnification] and representative flow cytometry dot plots). The B-lymphoblasts co-expressed CD371 (not shown), was indicative of an underlying DUX4 rearrangement (DUX4-r), which was subsequently confirmed by next-generation sequencing (NGS) analysis as a pathogenic IGH::DUX4 fusion.1 NGS also detected pathogenic variants of KRAS, NRAS, PTPN11 and an FLT3 internal tandem duplication mutation. Karyotyping revealed an isolated t(4;14)(q35;q32), and fluorescence in situ hybridization confirmed an IGH (14q32.33) rearrangement in 75% of cells. Following 8 days of standard induction chemotherapy, peripheral blood analysis (Figure, bottom row left to right: atypical monocyte morphology [Wright–Giemsa stain, objective ×100 magnification] and representative flow cytometry dot plots) identified residual B-lymphoblasts comprising 4% of cells (orange). In addition, a population of atypical monocytic cells (43%) was also detected (green) that expressed heterogeneous CD19, heterogeneous CD34 and co-expressed CD33, CD64 and CD14, consistent with a monocytic switch (MS) of leukaemic blasts. End of induction flow cytometric minimal residual disease evaluation of the bone marrow aspirate specimen demonstrated no evidence of residual atypical monocytes or B-lymphoblasts. The patient subsequently underwent consolidation therapy, including blinatumomab, without complications. Lineage infidelity and MS occurs in certain B-ALL subtypes, including those with mutated PAX5 P80R or rearrangements of DUX4, ZNF384 and CRLF2.2 In DUX4-r B-ALL, MS is a transient phenomenon occasionally observed during induction chemotherapy and is associated with an adverse event-free survival compared to DUX4-r B-ALL without MS. Recent single-cell ribonucleic acid sequencing study performed on DUX4-r leukaemic blasts demonstrated priming towards heterologous differentiation, including the monocytic and T-cell lineages in a subset of cases.3 Recognition of MS in the context of DUX4-r B-ALL during induction therapy is important to avoid its misdiagnosis as mixed phenotype acute leukaemia. Despite the slow initial response to induction chemotherapy and MS, DUX4-r B-ALL generally has a favourable outcome.4 The authors did not receive support from any organization for the submitted work. Retrospective review of pathology materials and clinical data was done with the approval by Cincinnati Children's Hospital Medical Center IRB. The authors have confirmed that a patient consent statement is not required for this submission, as no patient-identifying data were used. The authors declare no use of third-party material in this study for which formal permission is required.
Autor:innen und Institutionen
- Division of Pathology & Laboratory Medicine, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, USA.
- Department of Pathology & Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
ORCID-Profile: Jingwei Li
Zitieren
APA
Li, J., & Lorsbach, R. B. (2026). Monocytic transition in B‐lymphoblastic leukaemia with a DUX4 rearrangement. British Journal of Haematology, 208(5), 1519-1520. https://doi.org/10.1111/bjh.70407
Vancouver
Li J, Lorsbach RB. Monocytic transition in B‐lymphoblastic leukaemia with a DUX4 rearrangement. British Journal of Haematology. 2026;208(5):1519-1520. doi:10.1111/bjh.70407
BibTeX
@article{Li2026,
author = {Li, Jingwei and Lorsbach, Robert B},
title = {Monocytic transition in B‐lymphoblastic leukaemia with a DUX4 rearrangement},
journal = {British Journal of Haematology},
year = {2026},
volume = {208},
number = {5},
pages = {1519--1520},
doi = {10.1111/bjh.70407}
}
EUVIMED